LGALS9 and glioblastoma: For example, in a recent report, Li and colleagues used galectin-9-specific siRNA loaded into exosomes decorated with transferrin receptor-binding peptides to target glioblastoma cells and inhibit their growth, opening the way to novel immunotherapies of glioblastoma (64).